Developing Next-generation Therapies for Breast Cancer Patients

Breast cancer is the second most common malignancy worldwide and the number one cancer in women. In 2022, 2.3 million women were diagnosed with breast cancer, with 670,000 deaths globally. Fortunately, awareness, screening, and new treatment options are making a difference, but there’s still much work to be done.

Trends and advancements in breast cancer research

• Next-gen treatment modalities
  • Targeting oncodrivers, tumor associated antigens and neoantigens
  • Targeting immune response
  • Antibody-drug conjugates (ADCs)
  • Gene mutation inhibitors
  • Tumor infiltrating lymphocytes (TIL)
  • Vaccines
  • Oncolytic viruses
• Advancements in genomics and molecular profiling and predictive biomarkers, leading to individualized diagnosis and tailored therapies
• Treatments tailored to population sub-types, e.g., HER2 +/-, HR +/-
• Targeted therapies combined with chemotherapy or aromatase inhibitors

Challenges in breast cancer research

• Extremely competitive landscape
  • Highest number of studies and highest funding of all cancers—most researched
  • Challenging to bring in new research that will attract investigators and patients
• Numerous treatment options already approved
• More difficult to find suitable and treatment-naïve patients in North America and western Europe
• Need to eliminate the lack of diversity in clinical trial participants for breast cancer—mortality is 41% higher for Black women than White women

91% Corporate retention rate

• A transparent people-first culture with industry-leading retention
• We are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention guarantee program continuity, increased efficiency, and happy investigative sites

Exclusively biotech-focused

Built to work exclusively with biotechs, our flexible processes and approach allow us to listen first, align goals, and execute with an eye toward rapid shifts when protocols amend or Breakthrough designations move a product straight from Phase I to registration.

Seasoned oncology experts  

With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, Clinical Science), our oncology specialty guarantees you a seasoned team across all functions.

Additional differentiators 

Active next-gen oncology experience

Working both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.